[摘要]目的 探討吉西他濱聯(lián)合多烯紫杉醇治療晚期肺腺鱗癌的臨床效果。方法 選取2013年10月～2017年1月我院收治的92例晚期肺腺鱗癌患者作為研究對(duì)象，采用隨機(jī)數(shù)字表法將其分為觀察組和對(duì)照組，每組各46例。對(duì)照組患者給予多烯紫杉醇治療，觀察組患者在此基礎(chǔ)上給予吉西他濱進(jìn)行聯(lián)合治療。比較兩組患者的治療效果、平均生存時(shí)間（OS）及不良反應(yīng)發(fā)生情況。結(jié)果 觀察組患者的治療總有效率（91.30%）高于對(duì)照組（78.26%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者的平均OS為（25.59±4.59）個(gè)月，對(duì)照組患者的平均OS為（13.49±2.91）個(gè)月，觀察組患者的平均OS長(zhǎng)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者的不良反應(yīng)發(fā)生情況比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 吉西他濱聯(lián)合多烯紫杉醇治療晚期肺腺鱗癌的臨床效果顯著，可明顯提高患者的生存時(shí)間，具有較高的臨床應(yīng)用價(jià)值，值得推廣。
　　[關(guān)鍵詞]吉西他濱；多烯紫杉醇；晚期肺腺鱗癌；臨床效果
　　[中圖分類號(hào)] R814.42 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721（2018）2（b）-0138-03
　　The clinical effect of Gemcitabine combined with Dolitaxel in treatment of advanced lung adenoid squamous carcinoma
　　AN Shi-xing
　　Department of Oncology，the First Hospital in Laohekou City，Hubei Province，Laohekou 441800，China
　　[Abstract]Objective To explore the clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous carcinoma.Methods 92 patients with advanced lung adenocarcinoma treated in our hospital from October 2013 to January 2017 were selected as the study subjects，and were randomly divided into observation group and control group according to the random number table method，46 cases in each group.The patients in the control group were treated with Docetaxel，and the patients in the observation group were given Gemcitabine for combined treatment on this basis.The treatment effect，average survival time （OS） and adverse reactions were compared between the two groups.Results The treatment of total effective rate of patients in the observation group （91.30%） was lower than that in the control group （78.26%），and the difference was statistically significant （P<0.05）.In observation group，the average OS was （25.59±4.59） months，while the average OS in the control group was （13.49±2.91） months，the average OS in the observation was longer than that in the control group，and the difference was statistically significant （P<0.05）.There was no statistically significant difference in adverse reactions between the two groups （P>0.05）.Conclusion The clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous cell carcinoma is significant，which can obviously improve the survival time of patients and has high clinical application value and is worth promoting.
　　[Key words]Gisidhambin；Dolitaxel；Advanced lung adenoid squamous carcinoma；Clinical effect
　　肺腺鱗癌（ASC）是極其少見的一種癌癥，其患病率只有肺癌的0.6%～2.3%。臨床診斷肺部腫瘤中含有10%以上的腺癌或鱗癌成分才可判定為肺腺鱗癌，常位于外周并伴有中央瘢痕形成[1-3]。晚期ASC的生存概率是非常渺茫的，通常臨床應(yīng)用化療的方式來延緩患者的壽命。ASC屬于非小細(xì)胞肺癌的一種，化療對(duì)不同組織類型非小細(xì)胞肺癌所產(chǎn)生的效果也不同[4]，本研究選取我院收治的92例晚期ASC患者作為研究對(duì)象，探討吉西他濱聯(lián)合多烯紫杉醇治療晚期ASC的臨床療效，現(xiàn)報(bào)道如下。

相關(guān)熱詞搜索：紫杉醇 晚期 臨床 評(píng)價(jià) 效果